Company intelligence / Profile preview

Fujian Akeylink Biotechnology Co., Ltd.

Ownership: Private
Development stage: Other

Overview

The company has successfully developed Atilotrelvir/Ritonavir (GST-HG171/Ritonavir, also known as Taierteve or Tazovid), which received approval in China on November 23, 2023, for COVID-19 treatment. They also have multiple clinical-stage programs for hepatitis B and other indications.

Therapeutic areas: GastroenterologyOncologyInfectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

4 assets

Tazovid

3 more assets in the full pipeline.

Beyond the preview

Go deeper on Fujian Akeylink Biotechnology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fujian Akeylink Biotechnology Co., Ltd..